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Abstract 
Functional dyspepsia in children is classified as a subset of functional pediatric 
gastrointestinal disorders. According to ROME II criteria, it is divided into 3 groups 
including ulcer-like dyspepsia, dysmotility-like dyspepsia and unspecified (non-specific) 
dyspepsia. Prevalence of functional dyspepsia had been reported around 3/5 of 
children and adolescents who presented with clinical dyspepsia. Therefore, the 
appropriated investigations and management should be employed to rule out the 
possible organic causes of dyspepsia. To date there is no controlled treatment trial in 
children, however, from adult studies, histamine 2 receptor antagonists or proton pump 
inhibitor or prokinetic drugs are reasonable to be used as the first line treatment. As 
there are limited studies on childhood functional dyspepsia, we suggest that the good 
designed studies from children in all fields of this topic are required to ensure the 
appropriated recommendation. 
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Functional dyspepsia in children 
Functional dyspepsia, a childhood 
functional gastrointestinal disorders 
(FGIDs), refers to pain or discomfort 
centered in the upper abdomen. The 
discomfort can be upper abdominal 
fullness, early satiety, bloating, bleaching,  
 
queasiness, nausea, retching, or 
vomiting.
1
 Since the functional dyspepsia 
is not rigorously defined in children, the 
committee on Childhood Functional 
Gastrointestinal Disorders (Rome II) had 
adopted the adult diagnostic criteria for 
use in children (Table 1).
1
Table 1  Diagnostic criteria for functional dyspepsia in children (ROME II)
1
 
In children mature enough to provide an accurate pain history, the pain has to be 
present at least 12 weeks, which need not be consecutive, within preceding 12 months. 
The criteria for diagnosis are following. 
1. persistent or recurrent pain, or discomfort centered in the upper abdominal (above 
the umbilicus); and 
2. no evidence (including at upper endoscopy) that an organic disease is likely to 
cause the symptoms; and 
3. no evidence that dyspepsia is exclusively relieved by defecation, or associated with 
the onset of a change in stool frequency or stool form. 
 
Functional dyspepsia is divided into 3 
categories based on distinctive features.
1
 
1. Ulcer-like dyspepsia 
Pain centered in the upper abdomen is 
the predominant (most bothersome) 
symptom. 
2. Dysmotility-like dyspepsia 
An unpleasant or troublesome non-painful 
sensation (discomfort) centered in the 
upper abdomen is the predominant 
symptom. This sensation may be 
characterized by or associated with 
upper abdominal fullness, early satiety, 
bloating, or nausea. 
3. Unspecified (non-specific) dyspepsia 
Symptomatic patients whose symptoms 
do not fulfil the criteria for either ulcer-like 
or dysmotility-like dyspepsia are grouped 
into non-specific dyspepsia. 
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Diagnosis 
Functional dyspepsia can be 
diagnosed by exclusion of other organic 
diseases. Children who have a 
constellation of sign and/or symptoms 
shown in Table 2 that include 2 major 
criteria, one major and 2 minor criteria or 
4 minor criteria should be investigated to 
rule out the organic etiology of 
dyspepsia.
2
 The initial laboratory tests to 
screen for organic disease include 
complete blood count (CBC), urinalysis 
and urine culture, erythrocyte 
sedimentation rate (ESR), serum 
electrolytes, liver function tests and stool 
examination for ova and parasite. In 
selected cases, upper gastrointestinal 
series, serum amylase and lipase, or 
abdominal ultrasound may be required to 
rule out anatomic abnormalities, 
pancreatitis and gall bladder diseases, 
respectively. In patients who are 
suspected to have carbohydrate 
malabsorption or parasitic infestation, 
breath hydrogen test and stool studies for 
ova and parasite may be required. If the 
cause of dyspepsia cannot be identified 
by the initial investigations, an upper 
endoscopy with biopsies is the procedure 
of choice. The laboratory investigations in 
children with dyspepsia are shown in 
table 3. 
 
 Table 2  Criteria to define dyspepsia in children 
 
Major criteria Minor criteria 
Recurrent vomiting (at least 3/ month) 
Epigastric abdominal pain 
Chronic nausea 
Early satiety 
Excessive belching/ hiccups 
Anorexia/ weight loss 
Heartburn 
Periumbilical abdominal pain 
Oral regurgitation 
Positive family history of peptic ulcer disease, 
dyspepsia, or irritable syndrome  
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Table 3  Investigations of childhood dyspepsia 
 
Work up study Purpose 
Complete blood count (CBC), 
with differential white blood cell 
count 
Evaluate anemia, eosinophilia and infection 
Liver function tests Rule out liver and biliary tract disorders 
Stool ova and parasite Rule out parasitic infection 
Sedimentation rate If increased, rule out inflammatory bowel disease  
Serum amylase and lipase Rule out pancreatitis 
Ultrasound of liver Possibility of gallstones/ right upper quadrant pain 
Breath hydrogen test Evaluate for lactose intolerance and small bowel 
bacterial overgrowth 
Endoscopy  Rule out esophagitis, gastritis, duodenitis or 
Helicobacter pylori infection  
 
Prevalence 
Collecting the data from 400 consecutive 
unselected adult patients with dyspepsia 
who sought medical attention, Heikkinen 
and colleague
3
 revealed that 135 patients 
(34%) had functional dyspepsia, in which 
22% were ulcer-like, 28% were 
dysmotility-like and 50% were nonspecific 
dyspepsia. The study in children and 
adolescent
4
 aged more than 5 years old 
(n=257) who present with abdominal 
pain, discomfort and/or nausea for at 
least 1 month, revealed that 127 patients 
(49%) fulfill the criteria for dyspepsia. 
Endoscopy were performed in 56 
patients. While 21 children (38%) were 
found to have mucosal inflammation (10 
esophagitis, 12 gastritis and 7 
duodenitis), 35 children (62%) were 
considered to have functional dyspepsia. 
In children who had normal endoscopic 
finding, 70% were either asymptomatic or 
much improve after the 0.5 -1.9 year 
follow-up period. 
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Treatment 
To date, there is no controlled trial for 
treatment of functional dyspepsia in 
children. Therefore, the treatments based 
on the studies in adults will be discussed. 
1. Antacids 
In randomized controlled trial (RCT) 
studies, the absence of benefit of 
antacids over placebo is shown, neither 
the pain intensity (4%; 95%CI 12% to 
21%) nor the pain index (5%; 95%CI 
13% to 23%).
5
  
2. Histamine
2
 receptor antagonists 
(H2RA) 
The treatment outcomes of H
2 
receptor 
antagonists in functional dyspepsia have 
varied.
6-8
 The positive results of H2RA in 
some studies
9-18
 may be due to inclusion 
of GERD patients. Two large meta-
analysis studies showed the effectiveness 
of H
2
 receptor antagonists over placebo, 
including the improvement of epigastric 
pain (OR 2.33; 95%CI 1.63 to 3.32), the 
complete relief of epigastric pain (OR 
1.81; 95%CI 1.15 to 2.84) and the 
probability of treatment success.
19, 20
 
However, Redstone et al
19
 suggested that 
the study with larger sample size to  
 
 
determine the effective dose are 
necessary. 
3. Proton pump inhibitors (PPI) 
A large randomized controlled trial (RCT) 
study shows the effectiveness of 
omeprazole in treatment of functional 
dyspepsia, especially in ulcer-like and 
reflux-like dyspepsia.
21
 One thousand 
two-hundred and sixty two patients with 
functional dyspepsia (with normal upper 
GI endoscopy) were randomly selected to 
received one of the 3 following regimens, 
omeprazole 20 mg (O
20
), omeprazole 10 
mg (O
10
), or placebo (P) for 4 weeks. The 
patients who had the complete symptom 
relief were 38% in O
20
, 36% in O
10
 and 
28% in P (P value <0.05 compared with 
placebo). There was significant benefit of 
omeprazole over placebo in ulcer-like and 
reflux-like dyspepsia, but not dysmotility-
like dyspepsia. The study showed that the 
symptom relief in H. pylori-positive and 
negative cases were similar. However, H. 
pylori status may be a confounding factor 
on the treatment response. Blum et al
22
 
reported that high dose omeprazole was 
more likely to have positive effect in H. 
pylori infected patients. They showed that 
omeprazole (20 mg) has significant  
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therapeutic effect over placebo in H. 
pylori infected patients (17.6%; 95% CI 
4.2 to 31.0), but not in H. pylori negative 
patients (5.5%; 95% CI 8.0 to 19.1). Low 
dose omeprazole (10mg) or ranitidine 
(150 mg) has no significant effect over 
placebo.
  
 
4. Prokinetics 
The effectiveness of cisapride is generally 
better than placebo. However, some 
studies
7, 23
 did not shown the statistically 
difference between cisapride and 
placebo.
 
Domperidone and 
metoclopramide have shown a benefit 
over placebo in an available study.
6 
Recently, a meta-analysis study has 
shown the advantage of both cisapride 
and domperidone over placebo
24
 (OR 2.9; 
95%CI 1.5 to 5.8 and OR 7.0; 95%CI 3.6  
 
 
to 16 for cisapride and domperidone, 
respectively). Another meta-analysis 
study
20
 also showed the significant 
effectiveness of gastrokinetics (cisapride, 
domperidone) over placebo. The 
difference in proportions of treatment 
success compared to placebo for 
gastrokinetics is 0.4029 (95% CI 0.3042 
to 0.5069), including 0.3381 (95%CI 
0.2127 to 0.4635) for cisapride and 
0.5623 (95% CI 0.4828 to 0.6418) for 
domperidone. 
 
5. H. pylori eradication 
The prevalence of H. pylori in functional 
dyspepsia varies from 30-70% in adults
25
 
and 9% in children and adolescents.
4
 
Therapeutic efficacy of H. pylori 
eradication in functional dyspepsia is 
varied.
6
 In more recent large RCTs, the 
efficacy is still controversy (Table 4).
26-29
 
Table 4  Studies of Helicobacter pylori eradication and dyspepsia 
Author Design Treatment Results Comments 
Gilvarry 
et al
26
 
RCT  • Bisthmut
h based 
triple 
therapy 
(n 50) 
• Bismuth+
Triple therapy 
H.P.negative (n=42): 
significant response at 8 
wk, 6 mo, 1 yr (P<0.01) 
H.P.- positive: no 
decrease in symptoms 
Bismuth-placebo 
Eradication of HP*. 
results in a reduction 
of symptoms of non-
ulcer dyspepsia. 
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placebo  
(n 50) 
HP negative (n=7): 
improvement in 
symptoms at 8wk, 6 mo, 
1 yr 
HP positive: insignificant 
improvement 
McColl 
et al
27
 
RCT • OMA** or 
OMT 
(n=160) 
• O 
(n=158) 
• HP eradication: 88% 
vs 5% 
• Resolved symptom 
at 1 yr:  
21% vs 7% (95%CI for 
difference 7% to 22%, 
P<0.001)  
In HP infected, non-
ulcer like dyspepsia, 
treatment with 
omeprezole with 
antibiotics is more 
likely to resolved 
symptoms than 
treatment with 
omeprazole alone. 
Blum    
et al
28
 
RCT, 
multicenter 
• OMC 
(n=164) 
• O 
(n=164) 
• HP eradication: 79% 
vs 2% 
• Resolved symptom 
at 1 yr:  
27.4% vs 20.7% (95%CI 
for difference 2.6% to 
16.0%, P=0.17) 
HP eradication in non-
ulcer like dyspepsia is 
not likely to relieve 
symptoms. 
Talley et 
al
29
 
RCT, 
multicenter 
• OMA 
(n=135) 
• P*** 
(n=143) 
• HP eradication: 85% 
vs 4% 
• Resolved symptom 
at 1 yr:  
24% vs 22% (95%CI for 
difference 8% to 12%, 
P= 0.7) 
No evidence was 
found that eradication 
of HP relieves the 
symptoms of functional 
dyspepsia. 
*HP = Helicobacter pylori ** O = Omeprazole, M = metronidazole, T = Tetracycline, A = 
amoxycillin, C = clarithromycin; ***P = placebo 
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6. Other regimens 
6.1 Levosulpiride (levo-enantiomer of 
sulpiride) is a well-known antiemetic, 
antidyspeptic and antiphychotic drug. 
Corazza et al
30
 showed the significant 
effectiveness of levosulpiride (25 mg 
tid for 4 wk) over domperidone, 
metoclopramide and placebo 
(P<0.01) in treatment of functional 
dyspepsia.  
Compared with cisapride in a double-
blind crossover study (n=30)
31
, the 
efficacy of levosulpiride was similar in 
shortening (P<0.001) of gastric 
emptying time from the baseline. Both 
cisapride and levosulpiride improve 
all parameters of dyspeptic symptoms 
(P<0.001). Levosulpiride was superior 
to cisapride in the impact of 
symptoms on patients everyday 
activity and some symptoms such as 
nausea, vomiting and early satiety. 
However, no significant difference 
between them in regards to 
improvements in total symptom 
scores was observed. The clinical 
improvement had no significant 
correlation with gastric emptying 
acceleration (r=0.1) but another 
study
32
 reported that the effect of 
levosulpiride in improvement of 
symptom score correlated with gastric 
emptying time (r=0.47, P=0.01).  
 
6.2 Fedotozine acts on the kappa 
receptors located on afferent 
neurones in the gut wall. Read et al
33
 
reported the effectiveness of 
fedotozine (30 mg tid for 6 wk) in 
functional dyspepsia compared to 
placebo in RCT multicenter study 
(P=0.002). 
 
6.3 Simethicone  
Holtmann
34
 reported that the efficacy 
of simethicome was better than 
cisapride after 2-week treatment but 
not after 4-week treatment in 
functional dyspepsia. The 
improvement of symptom scores were 
30.7% (P<0.001) at 2 weeks and 
10.2% (P=0.11) at 4 weeks. 
 
6.4 Peppermint oil and caraway oil (PCC, 
Enteroplant) 
Madisch et al
35
 reported that the 
efficacy of a fixed combination of 
peppermint oil and caraway oil (n=60)  
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was comparable with the efficacy of 
cisapride (n=58) in functional 
dyspepsia (RCT study).  
 
7. Placebo  
Placebo produced a high symptomatic 
response rate in functional dyspepsia. In 
the systemic review trials it varied from 
13-73%.
9
 In a therapeutic trial with 
placebo
36
 (cellulose) three time daily 
before meal for 8 wk (n=30), 80% of 
patients reported improved global health 
status and markedly decreased symptom 
index (pre 23.9+/- 1.3 vs post 9.1+/- 1.2, 
P<0.05). Patients with functional 
dyspepsia had increased sensitivity to 
stepwise distension of stomach relative to 
healthy person and this finding remained 
unchanged after treatment even though 
improved clinical status.  
 
 
Summary 
There are a few studies about functional 
dyspepsia in children. Investigations in all 
fields of this topic are required. The 
definition of functional dyspepsia is still 
not clear especially in children (e.g., 
etiology, pathology). Therefore, the 
recruitment of patients for study should  
be careful.  Because of a lot of placebo 
effects, the study design should be a 
placebo-controlled trial. Even though bias 
may occur in studies, the available data 
of prevalence of dyspepsia in children 
and adolescents show that around 2/5 of 
dyspepsia are caused by organic 
diseases. Therefore, investigations, 
including gastroscope, should be done 
especially in children who have signs or 
symptoms suggestive of organic diseases 
(weight loss, vomiting), or persistent or 
recurrent symptoms despite the use of 
H2RA or PPI, or significant functional 
disability (extended school absenteeism, 
unable to participate in age-appropriate 
activities). There is no controlled 
treatment trial in children. Referred to the 
drug treatment in adult studies, H2RA or 
PPI or prokinetic durgs are reasonable to 
be used for treatment. The yields of H. 
pylori eradication in resolved symptoms 
of functional dyspepsia are still 
equivocally. More studies on other 
regimens are required before the 
recommendation. 
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